Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208156 · ClinicalTrials.gov registry record · Phase 3
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
A Phase 3 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
NCT00208156 is a Phase 3 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 87 participants.
The verdict
NCT00208156, a Phase 3 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
Study Summary
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. People who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. If Corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. The purpose of this study is to allow patients who have already participated in an earlier 8 week study of Corlux versus placebo (an inactive pill) to receive additional courses of treatment with Corlux periodically if a psychotic episode should reappear during a period of one year.
Interventions
- DRUG Mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00208156
The ClinicalTrials.gov registry entry for NCT00208156 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mifepristone is the first listed.
NCT00208156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00208156 about?
NCT00208156 is a clinical study titled "A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression". Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. People who suffer from psychotic majo...
What is the current status of trial NCT00208156?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2005-05. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00208156?
The interventions under investigation include: Mifepristone (DRUG).
Who is sponsoring clinical trial NCT00208156?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.